Can-Fite BioPharma

🇮🇱Israel

Country: 🇮🇱Israel

Ownership: Public

Established: 1994-01-01

Employees: 5

Market Cap: $12.2M

Website: http://www.canfite.com

Introduction: Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-...

Clinical Trials

Trial of CF101 to Treat Patients With Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Placebo
Drug: CF101

First Posted Date: 2010-12-23

Last Posted Date: 2020-11-18

Lead Sponsor: Can-Fite BioPharma

Target Recruit Count: 293

Registration Number: NCT01265667

Locations: 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
🇧🇬
City Center for Skin and Venereal Disease, Sofia, Bulgaria
🇮🇱
Haemek Medical Center, Afula, Israel

and more 15 locations

Trial of CF101 to Treat Patients With Dry Eye Disease

Phase 3

Completed

Conditions: Keratoconjunctivitis Sicca

Interventions: Drug: CF101

First Posted Date: 2010-11-05

Last Posted Date: 2022-06-30

Lead Sponsor: Can-Fite BioPharma

Target Recruit Count: 236

Registration Number: NCT01235234

Locations: 🇮🇱
Bnei Zion Medical Center, Haifa, Israel

Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: CF101
Drug: Placebo control

First Posted Date: 2009-12-17

Last Posted Date: 2022-05-24

Lead Sponsor: Can-Fite BioPharma

Target Recruit Count: 79

Registration Number: NCT01034306

Locations: 🇧🇬
Military Medical Academy, Sofia, Bulgaria
🇧🇬
UMHAT "Sveti Ivan Rilski", Rheumatoloty Clinic, Sofia, Bulgaria
🇧🇬
Diagnostic Consultative Center Sofia, Sofia, Bulgaria

and more 2 locations

Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure

Phase 2

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: CF101
Drug: Placebo for

First Posted Date: 2009-12-16

Last Posted Date: 2022-05-12

Lead Sponsor: Can-Fite BioPharma

Target Recruit Count: 89

Registration Number: NCT01033422

Locations: 🇧🇬
Specialized Hospital for Active Treatment for Eye Diseases "Zrenie", Sofia, Bulgaria
🇮🇱
Bnei Zion Medical Center, Haifa, Israel
🇧🇬
University Multiprofile Hospital for Active Treatment "Tsaritsa Yoanna - ISUL", Sofia, Bulgaria

A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee

Phase 2

Withdrawn

Conditions: Osteoarthritis of the Knee

Interventions: Drug: CF101
Drug: Placebo

First Posted Date: 2009-02-05

Last Posted Date: 2018-02-01

Lead Sponsor: Can-Fite BioPharma

Registration Number: NCT00837291

Locations: 🇮🇱
Barzilai Medical Center, Ashkelon, Israel

A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma

Phase 1

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: CF102

First Posted Date: 2008-11-13

Last Posted Date: 2022-05-17

Lead Sponsor: Can-Fite BioPharma

Target Recruit Count: 19

Registration Number: NCT00790218

Locations: 🇮🇱
Rabin Medical Center, Tel Aviv, Israel

A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1

Phase 1

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: CF 102
Drug: Placebo

First Posted Date: 2008-11-13

Last Posted Date: 2015-04-15

Lead Sponsor: Can-Fite BioPharma

Target Recruit Count: 32

Registration Number: NCT00790673

Locations: 🇮🇱
Rabin Medical Center, Tel Aviv, Israel

Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: CF101

First Posted Date: 2007-11-12

Last Posted Date: 2018-03-29

Lead Sponsor: Can-Fite BioPharma

Target Recruit Count: 253

Registration Number: NCT00556894

Locations: 🇧🇬
Clinic of Rheumatology at MHAT 'Sveti Georgi', Plovdiv, Bulgaria
🇧🇬
Clinic of Rheumatology at MHAT 'Sveti Ivan Rilski', Sofia, Bulgaria
🇵🇱
Wojewodzki Szpital Zespolony w Elblagu, Elblag, Poland

and more 23 locations

Safety and Efficacy Study of CF101 to Treat Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: CF101 1mg
Drug: CF101 2mg
Drug: CF101 4mg
Drug: Placebo

First Posted Date: 2007-01-30

Last Posted Date: 2023-02-08

Lead Sponsor: Can-Fite BioPharma

Target Recruit Count: 76

Registration Number: NCT00428974

Locations: 🇮🇱
Wolfson Medical Center, Holon, Israel
🇮🇱
Sheba Medical Center, Tel-Hashomer, Israel
🇮🇱
Haemek Medical Center, Afula, Israel

and more 1 locations

Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca

Phase 2

Completed

Conditions: Keratoconjunctivitis Sicca

Interventions: Drug: CF101
Drug: Placebo

First Posted Date: 2006-07-07

Last Posted Date: 2022-05-09

Lead Sponsor: Can-Fite BioPharma

Target Recruit Count: 80

Registration Number: NCT00349466

Locations: 🇮🇱
Sheba Medical Center, Tel Hashomer, Israel
🇮🇱
Meir Hospital, Kfar-Saba, Israel
🇮🇱
Assaf Harofeh Medical Center, Tsrifin, Israel

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy